Q3 EPS Estimate for Axsome Therapeutics Decreased by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Zacks Research lowered their Q3 2026 earnings per share estimates for Axsome Therapeutics in a research note issued to investors on Thursday, January 16th. Zacks Research analyst R. Department now expects that the company will earn $0.04 per share for the quarter, down from their prior forecast of $0.11. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share.

A number of other equities analysts also recently commented on the company. Mizuho reduced their price objective on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 31st. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price objective on shares of Axsome Therapeutics in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday. Royal Bank of Canada lifted their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $130.69.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $96.18 on Monday. The business has a 50 day simple moving average of $92.29 and a two-hundred day simple moving average of $89.61. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $105.00. The stock has a market capitalization of $4.66 billion, a P/E ratio of -14.73 and a beta of 1.04. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. During the same quarter in the prior year, the business posted ($1.32) earnings per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in Axsome Therapeutics during the 2nd quarter worth $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Axsome Therapeutics during the 2nd quarter worth $47,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after acquiring an additional 318 shares in the last quarter. Moors & Cabot Inc. acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth about $200,000. Finally, Whalen Wealth Management Inc. acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth about $236,000. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.